Trade

with

Acura Pharmaceuticals Inc
(NASDAQ: ACUR)
AdChoices
0.5901
+0.0049
+0.84%
After Hours :
-
-
-

Open

0.5967

Previous Close

0.5852

Volume (Avg)

33.92k (74.41k)

Day's Range

0.5800-0.6000

52Wk Range

0.5700-2.12

Market Cap.

28.83M

Dividend Rate ( Yield )

-

Beta

1.79

Shares Outstanding

48.85M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 123.00k

    • Net Income

    • -13.90M

    • Market Cap.

    • 28.83M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -7,290.26

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.79

    • Forward P/E

    • -2.04

    • Price/Sales

    • 147.06

    • Price/Book Value

    • 2.80

    • Price/Cash flow

    • -2.32

      • EBITDA

      • -13.76M

      • Return on Capital %

      • -65.56

      • Return on Equity %

      • -92.54

      • Return on Assets %

      • -65.56

      • Book Value/Share

      • 0.21

      • Shares Outstanding

      • 48.85M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Buy
        • 1 Year Price Target

        • 1.50

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -0.29

        • Cashflow Estimate

        • 0.14

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 3,400.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -69.21

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 0.51

            • 64.72

            • Pre-Tax Margin

            • -7,290.26

            • 13.77

            • Net Profit Margin

            • -7,290.26

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 0.89

              • 0.33

              • Current Ratio

              • 7.87

              • 1.52

              • Quick Ratio

              • 7.33

              • 0.87

              • Interest Coverage

              • -22.23

              • 6.77

              • Leverage Ratio

              • 2.12

              • 1.91

              • Book Value/Share

              • 0.21

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -2.02

                • 65.79

                • P/E Ratio 5-Year High

                • -31.20

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.95

                • 19.71

                • Price/Sales Ratio

                • 147.06

                • 3.69

                • Price/Book Value

                • 2.80

                • 3.46

                • Price/Cash Flow Ratio

                • -2.32

                • 22.12

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -92.54

                        (-30.20)

                      • 7.86

                        (9.58)

                      • Return on Assets %

                        (5-Year Average)

                      • -65.56

                        (-26.20)

                      • 4.14

                        (5.54)

                      • Return on Capital %

                        (5-Year Average)

                      • -54.37

                        (-26.60)

                      • 5.59

                        (7.66)

                      • Income/Employee

                      • -

                      • 27.79k

                      • Inventory Turnover

                      • 0.48

                      • 1.80

                      • Asset Turnover

                      • 0.01

                      • 0.38

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -14.09M
                      Operating Margin
                      -11,455.28
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -2.32
                      Ownership

                      Institutional Ownership

                      67.38%

                      Top 10 Institutions

                      67.04%

                      Mutual Fund Ownership

                      2.35%

                      Float

                      46.12%

                      5% / Insider Ownership

                      17.52%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Extended Market Index Fund

                      •  

                        408,034

                      • 0.00

                      • 0.84

                      • Vanguard Total Stock Mkt Idx

                      •  

                        290,832

                      • 0.00

                      • 0.60

                      • Vanguard Instl Total Stock Market Index

                      •  

                        205,102

                      • 0.00

                      • 0.42

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        93,798

                      • 0.00

                      • 0.19

                      • iShares Micro-Cap

                      •  

                        43,153

                      • 0.00

                      • 0.07

                      • Vanguard Balanced Index Fund

                      •  

                        37,896

                      • -10.61

                      • 0.08

                      • Schwab Total Stock Market Index Fund®

                      •  

                        20,900

                      • 0.00

                      • 0.04

                      • The Vanguard - Total Stk Mkt Idx Trust. CF

                      •  

                        18,555

                      • 0.00

                      • 0.04

                      • Master Extended Market Index Series

                      •  

                        11,590

                      • 0.00

                      • 0.02

                      • USAA Extended Market Index Fund

                      •  

                        11,585

                      • -0.04

                      • 0.02

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Essex Woodlands Health Ventures

                      •  

                        10,284,886

                      • -0.10%

                      • 20.02

                      • Vanguard Group, Inc.

                      •  

                        964,919

                      • +2.70%

                      • 1.98

                      • Geode Capital Management, LLC

                      •  

                        103,847

                      • -0.10%

                      • 0.21

                      • Creative Planning, Inc.

                      •  

                        89,844

                      • -14.76%

                      • 0.18

                      • Financial Advisory Service Inc

                      •  

                        81,983

                      • 0.00%

                      • 0.17

                      • Northern Trust Investments, N.A.

                      •  

                        80,382

                      • -0.35%

                      • 0.16

                      • Mariner Wealth Advisors, LLC

                      •  

                        52,018

                      • 0.00%

                      • 0.11

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Drug Manufacturers – Specific & Generic

                      Type

                      Distressed

                      Style

                      Small Value

                      Acura Pharmaceuticals Inc is a specialty pharmaceutical company engaged in the research, development and commercialization of products intended to address medication abuse and misuse, utilizing its proprietary Aversion and Impede Tec...morehnologies. The Company has discovered and developed two proprietary technologies; Aversion Technology and Impede Technology. Its Aversion Technology is a mixture of inactive ingredients incorporated into pharmaceutical tablets and capsules intended to address some common methods of product tampering associated with opioid abuse. Pfizer Inc.s Oxecta or oxycodone HCl tablets CII is the first approved and marketed product utilizing Aversion and is commercialized under its license agreement with a subsidiary of Pfizer, or the Pfizer Agreement. The Company has also developed ...moreits Impede Technology which is a combination of inactive ingredients that prevent the extraction of pseudoephedrine from tablets and disrupt the direct conversion of pseudoephedrine from tablets into methamphetamine. It has 7 additional opioid products utilizing Aversion in various stages of development. It also launched Nexafed commercially in mid-December 2012. The Pfizer Agreement grants Pfizer an exclusive license to develop and commercialize Oxecta. Its potential competitors include, Pain Therapeutics, in collaboration with Pfizer, Purdue Pharma, Atlantic Pharmaceuticals, Egalet Corporation, KemPharm, Shionogi, Nektar Therapeutics, Signature Therapeutics, QRx Pharma, Tris Pharma, Pisgah Labs, and Collegium Pharmaceuticals, Inc. The Company is subject to extensive regulation by the federal government, principally by the FDA under the Federal Food, Drug and Cosmetic Act, or the FD&C Act and to a lesser extent, by state and local governments.lessless

                      Key People

                      Robert B. Jones

                      CEO/Director/President

                      Peter A. Clemens

                      CFO/Chief Accounting Officer/Secretary/Senior VP

                      Dr. Albert W. Brzeczko,PhD

                      Vice President, Divisional

                      James F. Emigh

                      Vice President, Divisional

                      Robert A. Seiser

                      Vice President/Treasurer/Controller

                      • Acura Pharmaceuticals Inc

                      • 616 North North Court

                      • Palatine, IL 60067

                      • USA.Map

                      • Phone: +1 847 705-7709

                      • Fax: +1 847 705-5399

                      • acurapharm.com

                      Incorporated

                      2009

                      Employees

                      15

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: